Acute myeloid leukaemia (AML) is a highly heterogeneous haematopoietic stem cell malignant disorder and the most common malignant myeloid disorder in adults, with a median age of 70 years at presentation.1 Within this good practice paper we provide an update on developments specific to the older AML patient with frailty (a distinctive health state related to the aging process in which multiple body systems gradually lose their in-built reserves) where, historically, the potentially more effective intensive therapies have not been considered standard-of-care.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.